We used tuberculosis genotyping results to derive estimates of prevalence of latent tuberculosis infection in the United States. We estimated <1% prevalence in 1,981 US counties, 1%–<3% in 785 counties, and ≥3% in 377 counties. This method for estimating prevalence could be applied in any jurisdiction with an established tuberculosis surveillance system.

Approximately 25% of the world’s population is latently infected with Mycobacterium tuberculosis. Latent tuberculosis infection (LTBI) is an asymptomatic equilibrium between the immune response of the host and the infectious process. Although not infectious, LTBI can be activated years later as infectious tuberculosis (TB), which is why diagnosing and treating LTBI in high-risk populations is a key component of the World Health Organization End TB Strategy (1–4).

Most countries have established systems for surveillance of active TB. Public health interventions to control TB include timely detection and treatment of active cases and prompt investigations of persons with recent contact with someone who has infectious TB. However, few jurisdictions have estimates of local LTBI prevalence. Having such estimates could help direct TB prevention efforts for persons with the highest risk for infection, highest risk for progression to TB, and greatest benefit from treatment to prevent progression (2–4). We describe a simple method that uses genotyping results from active TB cases to derive a population estimate of untreated LTBI prevalence for any jurisdiction.

The Study
The US National TB Surveillance System contains 48,955 verified TB cases for 2011–2015. In the subset of 37,723 (77.1%) cases that were confirmed by culture, 36,104 (95.7%) had an M. tuberculosis isolate genotyped by the National TB Genotyping Service by using spacer oligonucleotide typing and 24-locus mycobacterial interspersed repetitive unit–variable number tandem repeat methods. The 50 US states and the District of Columbia are divided into 3,143 local jurisdictions (typically called counties). We used the US Census 2010 population denominator, annual TB incidence averaged during 2008–2015, and 2 assumptions for each county to derive an estimated prevalence of LTBI among residents.

For the 1,360 counties with no genotyped TB cases, which corresponded to 8% of the US population, we estimated local LTBI prevalence as <1%. For other counties, we assumed that all genotyped TB cases not attributed to recent M. tuberculosis transmission arose from preexisting LTBI (i.e., were reactivation TB). We used the previously field-validated plausible source-case method (5–7) to attribute cases to recent transmission (i.e., plausible source case within 10 miles within previous 2 years having infectious TB and a matching genotype result) for the District of Columbia and 49 US states. All cases diagnosed in non-US-born persons within 100 days of entry into the United States were excluded because the presumption was that these persons did not represent infection acquired in the United States. Because some cases in Oklahoma were missing geographic identifiers for identifying the 10-mile radius, a modification for these cases in this analysis was that the plausible source case could have occurred anywhere in the same county. Our second assumption was that the same recent transmission versus reactivation TB proportions for genotyped cases would apply to nongenotyped TB cases in each county (8).

Based on the estimate of Shea et al. (8) of ≈0.084 cases of reactivation TB/100 person-years among US residents with LTBI, we applied a uniform population-level 0.10% annual risk for progression to active disease to derive an estimated number of county residents with LTBI. As sensitivity analyses, we examined how LTBI prevalence estimates would decrease with a higher 0.14% uniform annual risk and how estimates would increase with a lower 0.06% uniform annual risk. We present estimates as uncertainty limits and provide the formula and examples of this method (Table 1).
We estimated that 3.1% (uncertainty limits 2.2%–5.2% based on higher or lower risk progression assumptions) of the US population, corresponding to 8.9 (6.3‒14.8) million persons, were latently infected with *M. tuberculosis* during 2011–2015. County-level estimates varied widely: estimated LTBI prevalence of <1% in 1,981 counties, 1%–<3% in 785 counties, and >3% in 377 counties (Figure). As defined by the US Census Bureau Small Area Income and Poverty Estimates, poverty in >20% of the population was a characteristic of 146 (72%) of the 202 rural counties and 62 (35%) of the 175 metropolitan counties that had an estimated LTBI prevalence >3% (Table 2).

**Conclusions**

Preventing TB is a growing focus of TB control strategies in the United States and internationally. As governments, public health departments, and private sector partners...
intensify TB prevention activities, having a tool to understand local variations in LTBI prevalence could help prioritize resources (2–4).

We used routinely collected TB surveillance and genotyping data to derive untreated LTBI prevalence estimates for all US counties. This method was designed to be simple (Table 1). By excluding the contribution of any TB cases attributed to recent transmission, our estimates disregard the comparatively smaller number of recent infections and instead draw attention to more longstanding LTBI prevalence. Because time since initial Mycobacterium tuberculosis infection was unknown, a uniform risk of recent transmission. Conversely, our overall estimate that 2.2%–5.2% of the US population is infected is similar to estimates from the 2011–2012 National Health and Nutrition Examination Survey (9).

For the United States, the last published nationwide county-level estimates of LTBI prevalence are based on 1958–1965 data, when 275,558 men 17–21 years of age who had lived their entire lives in 1 county were examined as they entered the US Navy (10). Men from poor counties in the southwestern United States and the Appalachian Mountains were more likely to have positive tuberculin skin test results (10). Compared with estimates from 5 decades ago, our estimates show a more diffuse pattern of higher LTBI prevalence counties (Figure). However, poverty remains a frequent characteristic of counties that we estimated as having a higher LTBI prevalence.

This method has limitations. We applied the proportion of genotyped TB cases in the county estimated to arise from preexisting LTBI to all nongenotyped TB cases in that county, which could overestimate the prevalence of LTBI in counties with many pediatric TB cases, which tend to be more difficult to confirm by culture techniques (i.e., cannot be genotyped), yet are sentinel events for recent transmission. Conversely, the genotyping methods used during 2011–2015 might have overestimated recent TB infections (i.e., underestimated LTBI prevalence) in certain localities with longstanding genotyping clusters;
this limitation should decrease as the National TB Genotyping Service transitions to universal whole-genome sequencing in 2018.

This method also has several advantages. It could be applied in jurisdictions without TB genotyping services, given an assumption or range of assumptions about the proportion of active TB cases arising from LTBI in the jurisdiction. Rather than relying on costly and imperfect LTBI screening methods, its starting point is verified cases of TB that are already routinely reported to established TB surveillance systems. If deemed applicable, an adjustment for underreported TB cases could be made. In addition, these cases represent infected persons who have the greatest risk for progression to active TB and are the populations most likely to benefit from interventions to prevent TB in the future.

Acknowledgments
We thank the clinicians, laboratory personnel, and public health staff who reported cases and contributed data to the US National TB Surveillance System and L. Allen, A.M. France, A. Langer, S. Marks, R. Miramontes, K. Schmit, B. Silk, and J. Wortham for providing helpful discussions about the analysis.

N.R.G. is supported by the National Institute of Allergy and Infectious Disease, National Institutes of Health (grant 1K24AI114444). K.G.C. is supported by an existing US Agency for International Development Intergovernmental Personnel Act agreement with Emory University.

About the Author
Ms. Haddad is an epidemiologist at the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, and a doctoral candidate at Emory University, Atlanta, GA. Her research interests include the history and social determinants of tuberculosis in North America.

References